Improvement in iron status and liver function in patients with transfusional iron overload with long-term subcutaneous desferrioxamine
- PMID: 87616
- DOI: 10.1016/s0140-6736(79)91721-5
Improvement in iron status and liver function in patients with transfusional iron overload with long-term subcutaneous desferrioxamine
Abstract
Subcutaneous desferrioxamine (2--4 g over 12 h) was administered 6 nights each week to 34 patients with transfusional iron overloads who continued to receive regular blood-transfusions. All 34 patients showed a fall in serum-ferritin after 5 to 12 months. In some patients serum-ferritin fell almost to normal. Liver function improved in all the patients, serum-aspartate-transaminase levels fell in all 17 patients tested, and liver-iron fell in 5 of 6 patients tested. These studies show that body-iron stores can be substantially reduced, to normal or near normal levels, by long-term subcutaneous desferrioxamine in patients with transfusional iron overload despite the need for continued blood-transfusion. They also show that removal of iron is accompanied by improved organ function.
Similar articles
-
Treatment of iron overload in adults with continuous parenteral desferrioxamine.Am J Med. 1977 Dec;63(6):958-66. doi: 10.1016/0002-9343(77)90551-4. Am J Med. 1977. PMID: 605917
-
Effect of dose, time, and ascorbate on iron excretion after subcutaneous desferrioxamine.Lancet. 1977 May 7;1(8019):977-9. doi: 10.1016/s0140-6736(77)92279-6. Lancet. 1977. PMID: 67469
-
Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload.Ann Hematol. 2006 May;85(5):315-9. doi: 10.1007/s00277-005-0075-z. Epub 2006 Feb 1. Ann Hematol. 2006. PMID: 16450126 Clinical Trial.
-
Deferasirox.Am J Health Syst Pharm. 2007 Mar 15;64(6):606-16. doi: 10.2146/ajhp060405. Am J Health Syst Pharm. 2007. PMID: 17353569 Review.
-
Results of long-term iron-chelating therapy.Acta Haematol. 1996;95(1):26-36. doi: 10.1159/000203853. Acta Haematol. 1996. PMID: 8604584 Review.
Cited by
-
Effect of ascorbic acid deficiency on serum ferritin concentration in patients with beta-thalassaemia major and iron overload.J Clin Pathol. 1982 May;35(5):487-91. doi: 10.1136/jcp.35.5.487. J Clin Pathol. 1982. PMID: 7085892 Free PMC article.
-
Korean guideline for iron chelation therapy in transfusion-induced iron overload.J Korean Med Sci. 2013 Nov;28(11):1563-72. doi: 10.3346/jkms.2013.28.11.1563. Epub 2013 Oct 31. J Korean Med Sci. 2013. PMID: 24265517 Free PMC article.
-
Hepatitis B virus infection in thalassemia major.Br Med J (Clin Res Ed). 1984 Aug 25;289(6443):500. doi: 10.1136/bmj.289.6443.500-a. Br Med J (Clin Res Ed). 1984. PMID: 6432162 Free PMC article. No abstract available.
-
Survival and desferrioxamine in thalassaemia major.Br Med J (Clin Res Ed). 1982 Apr 10;284(6322):1081-4. doi: 10.1136/bmj.284.6322.1081. Br Med J (Clin Res Ed). 1982. PMID: 6802413 Free PMC article. Clinical Trial.
-
Early iron overload in beta-thalassaemia major: when to start chelation therapy?Arch Dis Child. 1982 Dec;57(12):929-33. doi: 10.1136/adc.57.12.929. Arch Dis Child. 1982. PMID: 7181522 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources